JNJ

NEW BRUNSWICK, N.J., May 27, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson’s website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes. By telephone: for both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261. A replay of the conference call will be available until approximately 12:00 a.m. on July 29th. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13760885. The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call. Please refer to www.investor.jnj.com for a complete list of currently planned earnings webcast/conference calls. Please note the third-quarter date of Tuesday, October 13th, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/. View source version on businesswire.com: https://www.businesswire.com/news/home/20260527068310/en/ Contacts Media contact: media-relations@it...

Johnson & Johnson (NYSE:JNJ) is one of the best low risk stocks to buy in 2026. On May 5, Johnson & Johnson announced positive results from the first clinical study of its investigational OTTAVA Robotic Surgical System. The findings from the prospective, multicenter FORTE study evaluating the system in Roux-en-Y gastric bypass procedures were presented at the 2026 American Society for Metabolic and Bariatric Surgery/ASMBS Annual Meeting. In the 30-patient cohort, the study met its primary safety and performance endpoints through 30 days post-procedure, with investigators completing all surgeries robotically without converting to a non-robotic approach. The trial also showed the viability of the system’s novel architecture within space-constrained operating rooms. The system was successfully used across six hospitals, including multiple rooms historically considered too small or challenging for standard robotic setups. digitalreflections / Shutterstock.com Backed by these clinical and preclinical data, Johnson & Johnson (NYSE:JNJ) submitted an application to the US FDA for De Novo classification. The submission targets a general surgery indication covering multiple procedures within the upper abdomen, including gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia repair. Johnson & Johnson (NYSE:JNJ) is a global healthcare company that researches, develops, and manufactures pharmaceuticals and MedTech products. It focuses on treating complex diseases, advancing surgical care, and improving patient outcomes in areas such as cancer, immunology, and orthopedics. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.

AbbVie’s ABBV immunology franchise remained the company’s biggest growth driver in the first quarter of 2026, which beat expectations for both earnings and sales. The stronger-than-expected sales of Rinvoq and Skyrizi not only offset the continued erosion of legacy blockbuster Humira but also reinforced their importance as AbbVie’s key long-term growth drivers. Skyrizi sales increased 29.2% year over year to $4.48 billion, while Rinvoq generated $2.12 billion, up 20.2%. These upticks were fueled by strong volume growth and continued market share gains across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn’s disease (CD). During the first-quarter earnings call, management highlighted that Skyrizi continues to gain share in psoriatic disease and remains a leader in the frontline in-play patient share across both dermatology and rheumatology settings. The company also pointed to strong physician adoption in frontline inflammatory bowel disease (IBD) treatment settings, an important indicator of long-term market positioning. Regarding Rinvoq, AbbVie stated that demand remained strong across rheumatology, gastroenterology and dermatology markets, while highlighting improving prescription trends in ulcerative colitis following expanded label access supporting earlier-line use in IBD patients. Management’s confidence in the immunology franchise was reflected in updated 2026 guidance. AbbVie raised its sales expectations for both Skyrizi and Rinvoq by $100 million each. The company now expects Skyrizi revenues of approximately $21.6 billion and Rinvoq revenues of roughly $10.2 billion in 2026. Combined, Skyrizi and Rinvoq are expected to deliver more than 20% growth in 2026. Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs’ growth. Rinvoq could be approved for two indications — vitiligo and alopecia areata — in 2026/early 2027. In addition, phase III data on Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus are expected later this year. AbbVie believes that the next wave of potential approvals for Rinvoq could add roughly $2 billion to the pr...

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) Strengthened balance sheet with $100 million financing LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2026, and provided a corporate update. “Our achievements in the first few months of 2026 have materially strengthened MeiraGTx – we are now in a position to file for potential approval and launch two wholly-owned therapies in the next 2 years,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “The compelling three-year durability data from our AAV2-hAQP1 Phase 1 study continue to demonstrate disease-modifying benefit following a simple one-time treatment of patients with moderate to severe persistent radiation-induced xerostomia, an otherwise debilitating life-long condition. The recent receipt of Breakthrough Therapy Designation for this program reinforces the strength of the data and the potential for an expedited development and regulatory pathway.” Dr. Forbes continued, “We are very excited to have re-acquired bota-vec for the treatment of X-linked retinitis pigmentosa (XLRP). This is a highly strategic addition to our pipeline, given our long-term experience developing this drug while partnered with J&J, our deep expertise in ophthalmology, and our long-standing relationships with the inherited retinal disease patient community and KOL networks globally. Data from the Phase 3 LUMEOS study of bota-vec highlight the potential of this therapy to improve vision and significantly change the lives of those suffering with this otherwise inexorably degenerative disease. We are now working expeditiously to complete regulatory submissions in the U.S., EU, UK and Japan.” “To that end, I am extremely pleased to announce that Penny Fleck has joined MeiraGTx as Chief Development Officer,” said Dr. Forbes. “Penny brings tremendous experience from he...

It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have lost about 3.5% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Johnson & Johnson due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. J&J’s first-quarter 2026 earnings came in at $2.70 per share, which beat the Zacks Consensus Estimate of $2.67. Earnings declined 2.5% from the year-ago period. Adjusted earnings exclude intangible amortization expense and special items. Including these items, reported earnings were $2.14 per share, down 52.9% year over year. Sales came in at $24.1 billion, which also beat the Zacks Consensus Estimate of $23.44 billion. Sales rose 9.9% from the year-ago quarter, reflecting an operational increase of 6.4% and a positive currency impact of 3.5%. Organically, excluding the impact of acquisitions/divestitures and currency, sales rose 5.3% on an operational basis. Stelara’s LOE negatively impacted total revenue growth by 540 basis points. Excluding Stelara, sales grew in a double-digit range in the quarter. First-quarter sales in the domestic market rose 8.3% to $13.33 billion. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, domestic sales rose 6.2% in the quarter. International sales rose 11.9% on a reported basis to $10.7 billion, reflecting an operational increase of 3.9% and a positive currency impact of 8.0%. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, international sales rose 4.0% in the quarter. Innovative Medicines Segment J&J’s Innovative Medicines segment sales rose 11.2% year over year to $15.43 billion, reflecting a 7.4% operational increase and a positive currency impact of 3.8%. Excluding the impact of all acquisitions and divestitures and currency on an adjusted operational basis, worldwide sales rose 5.6%. Innovative Medicines sales beat the Zacks Consensus Estimate of $15.05 billion. Higher sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains drove the segment’s growth. New drugs like Carvykti, Tecvay...

Halozyme Therapeutics HALO reported first-quarter 2026 adjusted earnings of $1.60 per share, which beat the Zacks Consensus Estimate of $1.54. Earnings rose 44.1% year over year. Total revenues in the first quarter increased 42% year over year to $376.7 million. Revenues too surpassed the Zacks Consensus Estimate of $358 million. The top-line growth was primarily driven by an increase in product sales as well as higher royalty payments. HALO received royalty payments from Roche RHHBY for Phesgo and J&J JNJ for subcutaneous Darzalex (daratumumab), as well as argenx ARGX for Vyvgart Hytrulo. Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their currently marketed drugs. Halozyme now has several marketed partnered drugs based on this technology, including the subcutaneous (SC) formulation of J&J’s Darzalex, Roche’s Phesgo and argenx’s Vyvgart Hytrulo. Shares of Halozyme were up 3.6% in after-hours trading on Monday owing to the better-than-expected results. However, the stock has lost 1.3% year to date compared with the industry’s 2.6% decline. Image Source: Zacks Investment Research Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements. Royalty revenues totaled $240.7 million in the first quarter, up 43% from the year-ago quarter’s level. This was mainly due to the robust demand for RHHBY's Phesgo, JNJ's subcutaneous Darzalex and ARGX's Vyvgart Hytrulo, on which it earns royalties. Royalty revenues, however, missed our model estimate of $256.6 million. Product sales were $130.4 million in the first quarter, up 67.2% from the year-ago quarter’s level. HALO has two commercial proprietary products, Hylenex and Xyosted, with the latter acquired from Antares Pharma in 2022. Product sales beat our model estimate of $91.1 million. Revenues under collaborative agreements were $5.6 million in the reported quarter, down almost 70% year over year. Adjusted EBITDA was $229.5 million in the reported quarter, compared with $162 million in the year-ago quarter. Halozyme had cash, cash equivalents and marketable securities of $320.9 million as of March 31, 2026, compared with $145.4 million as of Dec. 31, 2025. Halozyme reiterated its total revenue guidance for 2026, which it had provided earlier this year. The company continues to expect total revenues in the range of $1.71 billion to $1.81...

Margins improved despite softer sales: Sales fell 3.2% to $344.8M, but adjusted EBITDA rose 9.5% to $28.7M and adjusted EPS increased 14.3% to $0.40, with consolidated gross margin up 190 bps; reported EPS was only $0.09 due to one‑time restructuring charges. Project Apollo driving cost savings but fuel is a risk: Management says plant consolidations are materially complete and the company remains on track for at least $20M of annualized Apollo savings, with additional G&A and distribution cuts expected, while higher fuel could create roughly a $3.5M H2 headwind if unmitigated. Active capital returns and product momentum: J&J repurchased $22M of stock this quarter (about $72M over 12 months) and paid $15.2M in dividends, while new-product shipments and strength in pretzels, Dogsters growth (and a Snoopy licensing deal) plus expanding ICEE tests support growth prospects. Interested in J & J Snack Foods Corp.? Here are five stocks we like better. Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look J & J Snack Foods (NASDAQ:JJSF) reported fiscal second-quarter 2026 results that showed margin expansion and higher adjusted earnings despite a decline in sales, as management pointed to benefits from its “Project Apollo” transformation and ongoing portfolio reshaping. Chief Executive Officer Dan Fachner said the company delivered “positive earnings and margin expansion despite a quarter that was impacted by demand softness amid rising fuel costs.” Adjusted EBITDA rose 9.5% year-over-year to $28.7 million and adjusted earnings per share increased 14.3% to $0.40. Sales declined 3.2% to $344.8 million. → 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries 3 Unstoppable Stocks To Cushion A VIX Spike, In One Sector Fachner said foodservice sales fell 5%, with “most of the decline attributed to the anticipated sales reductions in our bakery business consistent with Q1.” Retail sales declined 4.1%, which he attributed to “higher slotting fees and trade investments to support our innovation pipeline and brand share growth objectives.” Chief Financial Officer Shawn Munsell provided additional segment detail on the call: Foodservice: Net sales declined $11.4 million, or 5%, to $214.7 million. Munsell said about $8 million of the decline was due to planned reductions in a lower-margin bakery business. He also cited about a $4 million decline in cook...

Q1 revenue of $21.7M (+22% YoY) with record platform usage — ~108,000 genomic analyses in the quarter (including >40,000 patients in March) and a growing core customer base of 537 with net dollar retention of 117%. Commercial momentum driven by rising U.S. decentralized testing and faster adoption of newer applications — 100 customers signed for MSK-IMPACT/MSK-ACCESS (with ~3,000 liquid biopsy analyses in Q1, +100% YoY) and early biopharma deals with names like AstraZeneca and Johnson & Johnson. Solid unit economics and a clear path to profitability: adjusted gross margin ~75.4%, operating loss $17.3M and cash of $65.4M (plus a $25M expanded credit facility), while management reaffirmed 2026 revenue guidance of $92–$94M and expects to approach adjusted EBITDA breakeven by end-2026 and turn positive in H2 2027. Interested in SOPHiA GENETICS SA? Here are five stocks we like better. SOPHiA GENETICS (NASDAQ:SOPH) reported first-quarter 2026 revenue of $21.7 million, up 22% from $17.8 million in the prior-year period, as demand increased for its SOPHiA DDM analytics platform and the company expanded its installed base of clinical customers and applications. Co-founder and CEO Dr. Jurgi Camblong said the company “delivered revenue growth of 22% year-over-year” and completed a record 108,000 genomic analyses during the quarter. He said SOPHiA also set a monthly record in March with “more than 40,000 patients analyzed in a single month.” → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Chief Financial Officer George Cardoza said platform analysis volume was approximately 108,000 in Q1, up from 93,000 in the first quarter of 2025, representing 16% growth. Cardoza noted that year-over-year revenue growth “would have been slightly stronger” absent a one-time customer true-up benefit in the prior-year quarter. The company ended the quarter with 537 core genomic customers as of March 31, up from 490 a year earlier. Cardoza said annualized revenue churn remained “less than 1% in Q1,” while net dollar retention rose to 117% from 103% in the prior-year period. → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches President Ross Muken described three themes for the quarter, starting with increased U.S. momentum tied to growing acceptance of decentralized testing. Muken said that over the last 12 months, demand for decentralized testing...

Johnson & Johnson (JNJ) generates over $115 annually in passive income from a $5,000 investment. JNJ has raised its dividend for 64 consecutive years with a 2.39% indicated yield. The analyst who called NVIDIA in 2010 just named his top 10 stocks and Johnson & Johnson wasn't one of them. Get them here FREE. Passive income is the cash flow that arrives whether you are working, sleeping, or watching the market churn. For investors who have spent decades building a paycheck, the appeal of a portfolio that pays you on a fixed schedule is less about getting rich and more about getting reliable. Earned income stops the moment you do. Dividend income does not. Healthcare and consumer staples have long anchored income portfolios because their cash flows are largely insensitive to recession risk. The trade-off with a blue-chip name is yield: you give up the double-digit headline rate of a mortgage REIT or a BDC in exchange for a check that has not been cut, suspended, or skipped in living memory. For investors who want quarterly reliability over yield maximization, that trade is the entire point. We screened our 24/7 Wall St. dividend equity research database, looking for stocks that pay durable, growing dividends, and we found a Dividend King that can generate over $115 a year in passive annual income if you invest just $5,000 in it at the time of this writing. The analyst who called NVIDIA in 2010 just named his top 10 stocks and Johnson & Johnson wasn't one of them. Get them here FREE. Yield: 2.26% (indicated forward yield closer to 2.39% on the new $1.34 quarterly rate) Shares for $5,000: 22.3 at $224.20 Annual Passive Income: $119.54 (about $29.88 every quarter) Johnson & Johnson (NYSE:JNJ) is a diversified global healthcare company that operates two reporting segments after the Kenvue spin: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Six priority franchises, oncology, immunology, neuroscience, cardiovascular, surgery, and vision, drove $96.4 billion in trailing-twelve-month revenue and an operating margin of 27.4%. Q1 2026 revenue rose 9.9% YoY, led by DARZALEX, TREMFYA, CARVYKTI, and a MedTech cardiovascular business absorbing the STELARA biosimilar erosion without breaking stride. The dividend yield trails REIT and BDC standards, but the payout is engineered for permanence. JNJ is one of the few U.S. corporations carrying a prime AAA...

GSK plc GSK reported first-quarter 2026 core earnings of $1.26 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings rose 4% year over year on a reported basis and 9% at a constant exchange rate (CER), driven by higher sales turnover, favorable product mix and higher royalty income during the quarter. Quarterly revenues rose 2% on a reported basis and 5% at CER to $10.30 billion (£7.63 billion). This upside was attributed to the rising sales of its HIV, oncology and respiratory medicines. The top line also beat the Zacks Consensus Estimate of $10.19 billion. All growth rates mentioned below are on a year-over-year basis and at CER. GSK reports under three segments — General Medicines, Specialty Medicines and Vaccines. While sales in the Specialty Medicines increased 14%, the Vaccine segment rose 4%. Sales in the General Medicines segment, however, declined 6% on a year-over-year basis. HIV sales rose 10% in the first quarter of 2026, driven by an increase in patient demand for Dovato as well as long-acting medications, Apretude and Cabenuva. Sales in the quarter also benefited from favorable pricing due to channel mix, which offset the impact of regional pricing pressures. GSK generates the majority of its HIV sales from its dolutegravir franchise, comprising two-drug regimens — Dovato and J&J JNJ-partnered Juluca — and three-drug regimens — Triumeq and Tivicay. Dovato sales rose 20%, while those of the J&J-partnered Juluca declined 3%. Tivicay sales rose 2% during the quarter, while those of Triumeq fell 27%. Sales of Apretude and Cabenuva rose 44% and 31%, respectively. These two long-acting medicines currently account for more than a quarter of HIV sales. Oncology sales rose 28%, driven by strong demand for Jemperli, Ojjaara/Omjjara and Blenrep. Jemperli sales rose 40% during the first quarter, driven by increased patient uptake across the United States and Europe following the drug’s label expansion to treat all adult patients with primary advanced or recurrent endometrial cancer. Sales of the blood cancer drug Ojjaara/Omjjara rose 34%, primarily driven by strong patient uptake and continued commercial launches across Europe and international markets. U.S. volume growth was partly offset by ongoing pricing pressures. Zejula sales fell 11% in the quarter due to increased competition in Europe and significant...

Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Performing Dow Stocks So Far in 2026. On April 14, 2026, Reuters reported that Johnson & Johnson (NYSE:JNJ) topped first-quarter earnings projections and raised its full-year forecast. The firm reported revenue of $24.1 billion, above forecasts of $23.6 billion. The adjusted earnings per share were $2.70 as compared to $2.66 projected. Strong demand for Darzalex and Tremfya offset a significant dip in Stelara sales. Stelara sales fell over 60% year on year to $656 million when the patent expired. Tremfya’s quarterly sales were $1.6 billion, beating the $1.2 billion prediction. Darzalex delivered $4 billion, exceeding the $3.4 billion expectations. According to CFO Joseph Wolk, patients have shifted away from biosimilars in favor of other treatments. The corporation announced early success with Icotyde, pointing out approximately 1,500 prescriptions within weeks of launch. Johnson & Johnson (NYSE:JNJ) raised its sales forecast for 2026 to a midpoint of $100.8 billion and its adjusted EPS guidance to $11.55. Medical device sales rose by 7.7% to $8.6 billion, matching expectations. Trong Nguyen / Shutterstock.com Johnson & Johnson (NYSE:JNJ) is a holding corporation that researches, develops, manufactures, and sells healthcare products. It operates through two segments: Innovative Medicine and MedTech. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.

Johnson & Johnson’s JNJ first-quarter 2026 earnings came in at $2.70 per share, which beat the Zacks Consensus Estimate of $2.67. Earnings declined 2.5% from the year-ago period. Adjusted earnings exclude intangible amortization expense and special items. Including these items, reported earnings were $2.14 per share, down 52.9% year over year. Sales of this drug and medical devices giant came in at $24.1 billion, which also beat the Zacks Consensus Estimate of $23.44 billion. Sales rose 9.9% from the year-ago quarter, reflecting an operational increase of 6.4% and a positive currency impact of 3.5%. Organically, excluding the impact of acquisitions/divestitures and currency, sales rose 5.3% on an operational basis. First-quarter sales in the domestic market rose 8.3% to $13.33 billion. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, domestic sales rose 6.2% in the quarter. International sales rose 11.9% on a reported basis to $10.7 billion, reflecting an operational increase of 3.9% and a positive currency impact of 8.0%. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, international sales rose 4.0% in the quarter. J&J’s Innovative Medicines segment sales rose 11.2% year over year to $15.43 billion, reflecting a 7.4% operational increase and a positive currency impact of 3.8%. Excluding the impact of all acquisitions and divestitures and currency on an adjusted operational basis, worldwide sales rose 5.6%. Innovative Medicines sales beat the Zacks Consensus Estimate of $15.05 billion. Higher sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains drove the segment’s growth. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato contributed significantly to growth. The sales growth was partially dampened by biosimilar competition to blockbuster drug Stelara and lower sales of Imbruvica. Sales of blockbuster multiple myeloma medicine Darzalex rose 22.5% year over year to $3.96 billion in the quarter. Sales beat the Zacks Consensus Estimate of $3.85 billion. Imbruvica sales declined 6.9% to $660.0 million. Rising competitive pressure in the United States due to new oral competition has been hurting Imbruvica's sales for the past few quarters. Imbruvica sales were, however, better than the Zacks Consensus Estimate of $...